Lena Zewdu Feleke is a senior at Martin Luther King Jr. Magnet High School and a student from the School for Science and Math ...
China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...
RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback